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Abstract 
Purpose 
Recent studies have established psoriasis as an independent risk factor for the development of 
cardiovascular disease. The aim of this study was to evaluate, with clinical, analytical and imaging 
methods, the effects of the systemic proinflammatory state induced by psoriasis on cardiac 
remodelling and evaluate Diastolic Dysfunction (DD) as an early marker of cardiovascular 
involvement. 
Methods 
This study enrolled 38 consecutive psoriasis patients (47,5 years, 68,4% males). Clinical 
information and evaluation of inflammatory markers were collected. Diastolic function was 
assessed by two-dimensional transthoracic echocardiography and speckle-tracking.  
Results 
This exhaustive description of statistically relevant data, and its variation according to the widely 
accepted diastolic dysfunction markers, found that in patients with both LA maximum volume 
index >34 mL/m2 and LV GLS >-20%, the average PASI was highest, as well as hsCRP values. 
In this study, 60% of patients presented a value above 34 mL/m2 and 51,4% presented LV GLS 
>-20%. E/A ratio below 0,75 was found in 10,8%, 8,1% had values above 1,5 and 44,4% had DT 
greater than 220 ms. 
Conclusion 
Echocardiography analysis, particularly with STE shows promising prospects in early 
identification of diastolic dysfunction in psoriatic patients. Also, hsCRP may have a role in 
detecting low grade inflammatory states and predict long-term repercussions of chronic 
inflammatory states. 
 
Keywords 
Psoriasis, Systemic Inflammation, Diastolic Dysfunction, Echocardiography Transthoracic, 
HFpEF 
 
  
 IV 
 
Resumo 
Objetivo 
Hodiernamente, a psoríase é considerada um fator de risco independente para o desenvolvimento 
de doenças cardiovasculares. O objetivo deste estudo foi avaliar, recorrendo a meios clínicos, 
analíticos e imagiológicos, os efeitos do estado pro-inflamatório sistémico induzido pela psoríase 
no remodelling cardíaco e analisar a Disfunção Diastólica como um marcador precoce do 
envolvimento cardíaco. 
Materiais e Métodos 
Foram incluídos sequencialmente 38 doentes psoriáticos (47,5 anos, 68,4% homens). A 
informação clínica e análise dos parâmetros analíticos foram colhidas na consulta e por amostras 
sanguíneas. A função diastólica foi avaliada através do ecocardiograma transtorácico, recorrendo 
a STE.  
Resultados 
A descrição exaustiva dos parâmetros estatisticamente relevantes e a sua variação de acordo com 
os marcadores de disfunção diastólica amplamente aceites permitiu concluir que, nos doentes com 
volume indexado aurícula esquerda >34 mL/m2 e GLS do ventrículo esquerdo >-20%, o PASI 
médio foi mais elevado, bem como os valores médios de hsCRP. Neste estudo, 60% dos doentes 
revelaram a volume indexado aurícula esquerda >34 mL/m2 e 51,4% apresentaram GLS do 
ventrículo esquerdo >-20%. E/A inferior a 0,75 foi observado em 10,8% dos doentes, 8,1% 
apresentaram valores superiores a 1,5 e 44,4% apresentou DT maior que 220 ms. 
Conclusões 
A avaliação ecocardiográfica, particularmente por STE, revela perspetivas promissoras no que à 
identificação precoce de disfunção diastólica em doentes com psoríase concerne. Do mesmo 
modo, a hsCRP poderá representar um papel na deteção de estados inflamatórios de baixo grau e 
predição de repercussões a longo prazo deste estado inflamatório crónico. 
 
Palavras-Chave 
Psoríase, Inflamação Sistémica, Disfunção Diastólica, Insuficiência Cardíaca com Fração de 
Ejeção Preservada, Ecocardiograma Transtorácico  
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Abbreviations/Acronyms 
BMI Body Mass Index 
BP Blood Pressure 
BSA Body Surface Area 
C3 Complement Component 3 
DD Diastolic Dysfunction 
DT Deceleration Time 
EF Ejection Fraction 
FS Fractional shortening  
GLS Global Longitudinal Strain 
HbA1c Glycated hemoglobin 
HDL High-Density Lipoprotein 
HEPA Health Enhancing Physical Activity 
HFPEF Heart Failure with Preserved Ejection Fraction 
hsCRP High-Sensitive C-Reactive Protein 
ICD Implantable Cardioverter Defibrillator 
IL Interleukin  
IPAQ International Physical Activity Questionnaire 
LA Left Auricular 
LDL Low-Density Lipoprotein 
LV EDV/ESV Left Ventricular End-Diastolic/End-Systolic Volume 
LV Left Ventricle 
NT-proBNP N-terminal pro-B-type Natriuretic Peptide 
PACS Peak Atrial Strain before Atrial Contraction 
PALS Peak Atrial Strain at the End of Ventricular Systole 
PASI Psoriasis Area and Severity Index 
 VI 
 
PsA Psoriatic Arthritis  
QoL Quality of Life 
SD Standard Deviation 
SPSS Statistical Package for the Social Sciences 
STE Speckle-Tracking Echocardiography 
TNF-α Tumor Necrosis Factor α 
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1. Introduction 
Psoriasis is a chronic, immune-mediated and disabling inflammatory disease, with systemic 
involvement and great burden on both patients’ quality of life (QoL) and health care systems. 
Registration of psoriasis cases is not compulsory, which means that its exact incidence is difficult 
to determine in the general population. Nevertheless, recent studies reported an incidence rate 
between 78.9/100,000 and 230/100,000 person-years in the adult population.[1] The reported 
prevalence of this disease in countries ranges between 0,09% and 11,4%. [2] According to a 2000 
study in a Portuguese sample estimated a prevalence of 1,9%.[3] There is evidence to suggest that 
the prevalence of psoriasis may be increasing.[4] The variation in prevalence and severity is 
influenced by important factors, including age, geography and ethnicity.[1] Even though psoriasis 
is associated with low mortality rates, it has a great morbidity. 
Psoriasis can occur at any age. However, some studies suggested that its onset can be bimodal 
with the first peak of the disease between 16 and 22 and the latter between 57 and 60 years of age. 
This disease has an equal sex distribution[5], but is epidemiologically more relevant in caucasians. 
The etiology of psoriasis remains unclear, however there is evidence that different endogenous or 
environmental triggers like infection, mild trauma, systemic drugs (lithium, antimalarials and 
nonsteroidal anti-inflammatory drugs), sunburn, obesity and stress initiate or worsen this 
multifactorial syndrome in genetically prone individuals. Risk factors are recognized, including 
family history and environmental risk factors, such as smoking, stress, obesity, and alcohol 
consumption.[1] 
Psoriasis involves the skin and nails, with localized or generalized lesions, mostly symmetrical, 
sharply demarcated, red papules and plaques, and usually covered with white or silver scales.[2] 
The most frequently reported symptoms connected to psoriasis include scaling of the skin in 92%, 
pruritus in 72%, erythema in 69% fatigue in 27%, swelling in 23% and in 20% burning or 
bleeding.[2]  
Recent studies have suggested that there is an overexpression of various proinflammatory 
cytokines (Interleukin (IL)-1, IL-6, IL-8, IL-12, IL-15, IL-17-20, IL-22, IL-23), TNF-α and 
interferon-γ, inflammatory markers (C3, C4) and adipokine’s system disorders not only in skin 
lesions, but in the entire organism as well. Therefore, these individuals are at a great risk of 
developing different systemic comorbidities including  psoriatic arthritis, diabetes mellitus, 
obesity, hypertension, coronary heart disease[6], liver disease[7], inflammatory bowel disease[8], 
lymphoma and depression. Patients diagnosed with psoriasis have an increased burden of 
subclinical conditions such as atherosclerosis, vascular inflammation, endothelial dysfunction[9] 
and higher levels of serum lipids, including triglycerides and total cholesterol.[10] The greater 
The Effect of Psoriasis on Diastolic (Dys)Function –  A Pilot Echocardiographic Study 
 
9 
 
severity of psoriasis has been associated with an enhanced oxidative stress and dyslipidemia, 
implying that the risk of cardiovascular events may be higher in severe psoriasis.[11]  
Different pathophysiological mechanisms can be responsible for the association between psoriasis 
and cardiovascular disease, such as the high prevalence of cardiovascular risk factors in psoriasis 
patients or the systemic proinflammatory response induced by psoriasis. Furthermore, psoriasis 
has been established as an independent risk factor for cardiovascular disease.[12] 
Recent studies have been ascertaining the involvement of a systemic proinflammatory state 
induced by various non-cardiac comorbidities, as a main determinant of Diastolic Dysfunction 
(DD) and Heart Failure with Preserved Ejection Fraction (HFPEF). The circulating levels of 
inflammatory cytokines, such as interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) and 
pentraxin 3[13, 14], can cause coronary microvascular endothelial inflammation and lead to the 
decrease of nitric oxide bioavailability, cyclic guanosine monophosphate and protein kinase G 
activity in adjacent cardiomyocytes.[15] These reactions favour hypertrophy development and 
stiff cardiomyocytes, because of hypophosphorylation of the cytoskeletal protein titin[16], which 
ultimately may lead to concentrically remodelled Left Ventricle (LV) with DD.[13] The 
peripheral endothelial dysfunction is independently correlated with future cardiovascular 
events.[17] 
DD is defined as an abnormality of the left ventricle to relax and/or to fill with an adequate blood 
volume, and is an independent risk factor for the development of heart failure and long term 
mortality[18]. Subclinical DD is common within the population, with a prevalence up to 25% 
[19], particularly amongst older, hypertensive, diabetic and obese people, although some may 
remain asymptomatic and don’t even develop further heart failure.  
It is plausible to think that also in the systemic proinflammatory state due to psoriasis, DD can be 
an early marker of cardiovascular involvement and heart failure risk. Although patients are well 
informed about their skin lesions, they have insufficient knowledge of their risk of 
atherothrombotic disease and metabolic syndrome.[20] Hence, early identification and 
management of subclinical changes in myocardial structure and function, and their determinants, 
as well as other comorbidities, can be particularly important in psoriatic patients. This allows a 
more efficient and effective clinical practice, an increase patients' quality of life, a reduction of 
costs associated with therapeutics and an improve the success of established treatments. 
Through this investigation and with the aid of available clinical, analytical and imaging methods, 
we pretend to evaluate patients with psoriasis and infer about their inflammatory state, 
cardiovascular risk factors and cardiac function, particularly diastolic function. 
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2. Methods 
This study is a cross-sectional institutional investigation and there will be included a sequential 
sample of patients with psoriasis evaluated in the Dermatology Department consult of Centro 
Hospitalar do Porto. All participants provided written informed consent to participate in the 
investigation. 
 
2.1 Patients 
The study group included 38 individuals. In this analysis, we included patients with moderate-to-
severe psoriasis above the age of 18. Individuals presenting with cardiovascular disease, such as 
previous cardiovascular disease, ischemic heart disease, valvulopathy, heart failure, cardiac 
dysrhythmia, coronary artery bypass surgery, coronary angioplasty, valvuloplasty, pacemaker or 
Implantable Cardioverter Defibrillator (ICD) or any cardiothoracic surgery, were excluded from 
this study due to the higher likelihood of introducing further biases. 
 
2.2 Clinical Evaluation 
All patients were submitted to clinical interview to collect data on sex, age, current smoking 
status, International Physical Activity Questionnaire (IPAQ) short form for physical activity[21], 
family history of cardiovascular disease, comorbidities or ongoing medication. Regarding 
psoriasis, information on family history, disease duration, diagnosis of psoriatic arthritis (PsA) 
and use of biologic therapy was gathered. Besides, height, weight, abdominal perimeter, blood 
pressure (BP), cardiac frequency and body mass index (BMI) were measured during consultation. 
Psoriasis severity was graded according to the gold standard score[22, 23] Psoriasis Area and 
Severity Index (PASI) score. PASI is a combined score consisting of a measurable evaluation of 
the plaque’s degree of erythema, induration, and desquamation, based on four anatomical areas 
(head, arms, trunk and legs), weighted according to the area’s proportion of the body and assigns 
a final score which ranges from 0 to a theoretical maximum of 72. To diminish subjectivity, the 
PASI was evaluated by the same dermatologist in all patients.  
Regarding the categorization of the variables for ensuing statistical evaluation, IPAQ was divided 
in inactive, minimally active and Health Enhancing Physical Activity (HEPA active)[24]; family 
history of cardiovascular disease was considered present when first and/or second degree family 
members were affected; diabetes mellitus, dyslipidemia, hypertension, depression and/or ongoing 
medication counted for the presence of comorbidities; abdominal perimeter was divided in below 
or above 88 cm for females and below or above 120 cm for males; systolic BP was classified in 
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below or above 140 mmHg and diastolic BP in below or above 90 mmHg;[25] BMI included 4 
categories (< 18,5 kg/m2 underweight; 18,5-24,99 kg/m2 normal range; 25-29,99 kg/m2 
overweight; >30 kg/m2 obese).[26] 
About psoriasis, family history was considered positive when first and/or second degree family 
members were affected; psoriasis duration was divided in decades; presence or absence of 
previous diagnosis of PsA; use of biologic therapy or not; psoriasis’ severity was graded as 
PASI≤10 or PASI>10[23];  
 
2.3 Laboratory Evaluation 
Blood samples were collected from the subjects at the time of their clinical evaluation, and total 
cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, 
apolipoprotein B, glucose, glycated haemoglobin (HbA1c), insulin, N-terminal pro-B-type 
natriuretic peptides (NT-proBNP), complement component 3 (C3) and high sensitive C-reactive 
protein (hsCRP) were measured. 
These variables were categorized for statistical purposes, according to the most recent guidelines 
for clinical practice[27]: total cholesterol in below or above 200 mg/dL, LDL in below or above 
100 mg/dL, HDL on females was divided in below or above 48 and on males in below or above 
40, triglycerides in below or above 150 mg/dL, apolipoprotein B in below or above 100 
mg/dL[27], HbA1c in below or above 6,5%, C3 in below or above 135 mg/dL and hsCRP in 
below or above 3 mg/L. 
 
2.4 Echocardiography Protocol 
All patients were submitted to detailed Transthoracic Echocardiography assessment, by a single 
experienced cardiologist, using an ultrasound system (Siemens Acuson SC2000). Images were 
digitally stored for posterior offline analysis. The exams were screened for adequate quality 
imaging to perform Speckle-Tracking Echocardiography (STE) analysis, subsequently those 
studies with poor imaging quality were excluded (n=1). Cardiac chamber volumes and 
dimensions were measured according to current recommendations.[28] Diastolic function was 
assessed according to the 2016 European Echocardiography Association and American Society 
of Echocardiography Consensus Criteria on Diastolic Function Evaluation[29]. Each measure 
was performed in triplicate and the mean value was used for analysis and a minimum of three 
cardiac cycles were recorded. All values were indexed to body surface area. 
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LV volumes were determined using the modified Simpson’s method using apical 2 and 4 
chambers views (Figures 1 and 2) at an end-systolic and end-diastolic frames and was indexed to 
Body Surface Area (BSA) to estimate LV EDVi and LV ESVi. Systolic function was assessed by 
calculating the Ejection Fraction (EF), using the same method and by analysing systolic 
myocardial annular tissue velocity (S’ septal, S’ lateral and S’ mean). For statistical purposes, LV 
EDVi was categorized as above or below 74 mL/m2 for men and 61 mL/m2 for women and LV 
ESVi as above or below 31 mL/m2 for men and 24 mL/m2 for women; LV EF was divided in 
below or above 52% for men and below or above 54% for women. Mitral valve inflow 
measurements, such as early filling velocity (E), late filling velocity (A), E/A ratio and early 
filling deceleration time (DT) were assessed by pulsed wave Doppler. 
From LA speckle tracking analysis (Figure 3), we extracted LA phasic volumes, such as: pre-A 
wave LA volume, maximum and minimum LA volumes. LA function indexes were calculated 
using these values and validated formulas. LA reservoir function was evaluated using LA 
emptying fraction as [(maximum LA volume - minimum LA volume) / maximum LA volume x 
100] and LA expansion index as [(maximum LA volume - minimum LA volume) / minimum LA 
volume x 100]. LA conduit function was determined using LA passive emptying volume as 
(maximum LA volume - pre-A wave LA volume), LA passive emptying fraction as [(maximum 
LA volume – pre-A wave LA volume) / maximum LA volume]. LA booster pump function using 
LA active emptying fraction [(pre-A wave LA volume - minimum LA volume) / pre-A wave LA 
volume], and LA active emptying volume (pre-A wave LA volume - minimum LA volume). From 
the average of the strain curves of all segments we evaluated peak LA strain at the end of 
ventricular systole (PALS), peak atrial strain before atrial contraction (PACS), Systolic Strain 
Rate; Early Diastole Strain Rate; Late Diastole Strain Rate. LA passive emptying strain was then 
calculated as (PALS - PACS), which is a measure of LA conduit function. Two-dimensional STE-
derived Left Auricular Longitudinal Strain (LALS) was calculated using average deformation. 
LALS was categorized in above or below 11,5%.[30] 
 
2.5 Statistical Analysis 
The statistical analysis was performed using the Statistical Package for the Social Sciences 24 
(SPSS). Continuous variables are expressed as Mean ± Standard Deviation (SD), non-normally 
distributed variables as Median and Interquartile Range and categorical variables are reported as 
frequency and respective proportion (%).  
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3. Results 
3.1 Patients characteristics 
41 psoriasis patients were initially included, however 4 dropped out due to unavailability of 
attending the echocardiogram. The final study group counted for 38 patients, 68,4% (n=26) of 
whom were males with a median age of 47,5 (P25 38,8; P50 47,5; P75 56,3) years old and 36,8% 
were current smokers. The mean BMI was 27,6±4,5 kg/m2; 55,3% of patients were overweight 
and 23,7% were obese. High abdominal perimeter was found in a total of 50% and 21% presented 
hypertension. HbA1c above 6,5% was observed in 3,4 %.  
Regarding psoriasis, the mean PASI presented at consultation was 3,2±3,5; 94,7% had PASI <10 
and 5,3% had PASI >10. The disease duration was up to 20 years in 52,6%. 92,1% of patients 
were on biologic therapy, which included ustekinumab, etanercept, secukinumab, infliximab and 
adalimumab. Posterior PsA diagnosis was referred in 44,7% of patients. The study group 
demographic and clinical characteristics can be consulted in Table 1. 
 
3.2 Analytic variables  
The mean values for lipid profile were 117±41 mg/dL for LDL, HDL 52±13 mg/dL, total 
cholesterol 196±41 mg/dL, triglycerides 114±72 mg/dL, apolipoprotein B 102±22 mg/dL. 64,5% 
had LDL values >100 mg/dL; 25,8% had HDL values <48 mg/dL for females or <40 mg/dL for 
males; 38,7% had total cholesterol values >200 mg/dL; 16,1% had triglycerides values >150 
mg/dL; 55,2% had apolipoprotein B values >100 mg/dL. 
Regarding the inflammatory markers C3 and hsCRP, the mean value for the first was 115,33±21,5 
mg/dL and 3,6±3,9 mg/L for the latter. 13,8% had levels of C3 >135 mg/dL and 38% had hsCRP 
values >3 mg/L. The mean NT-proBNP value was 40,4±38,4 pg/mL. The analytic patients’ 
characteristics can be consulted in Table 2. 
 
3.3 Echocardiographic variables 
This study included patients with preserved ejection fraction (mean left ventricular ejection 
fraction 58±3%), with a mean 9,97±1,8 mm septal wall thickness, 8,99±1,6 mm posterior wall 
thickness. The average LV EDVi and LV ESVi values were 52,77±34,65 mL/m2 and 19,07±4,51 
mL/m2, respectively. 
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Regarding diastolic function evaluations, the mean E velocity was 71,7±12,3 cm/s, A 69,8±13,1 
cm/s, DT 222±55,6 ms and E/A ratio 1,08±0,32. E/A ratio below 0,75 was found in 10,8% and 
8,1% had values above 1,5. DT was greater than 220 ms in 44,4% patients. 
The average medial e’ was 10,5±2,7 cm/s, lateral e’ 13,7±4 cm/s and an average e’ of 12,1±3,3 
cm/s. 18,4% (n=7) presented lateral e’ < 10cm/s and 8,1% (n=3) presented medial e’ < 7 cm/s. 
The respective medial E/e’ was 7,2±1,7, lateral E/e’ was 5.5±1,3 and the average E/e’ 6,3±1,4. 
No patient presented average E/e’ > 13. 
STE-derived LA strain and volumes are exhaustively described below and can be consulted in 
Table 3. The LA maximum atrial volume’s mean was 69,8±21,6 mL, LA pre-A wave atrial 
volume 37±16,4 mL and the LA minimum atrial volume was 18,2±9,4 mL. The mean LA 
maximum volume index was 36,7±10,2 mL/m2 and 60% presented a value above 34 mL/m2. 
Concerning the reservoir LA function, mean LA emptying fraction was 74,5±8,1 and the mean 
LA expansion index was 359,5±158,9. About the conduit LA function, the LA passive emptying 
volume was 31,6±12,9 mL and respective LA passive emptying fraction was 47,6±16,3; the 
PALS-PACS, passive emptying strain, mean value was 32,2±17,1. Regarding booster pump LA 
function, the LA active emptying volume was 19±8,9 mL and the LA active emptying fraction 
was 51,9±11. The mean PALS was 51,3±18,6 % and the mean PACS value was 19,5±7,8 %; 
PALS-PACS mean value was 32,2±17,1. The mean systolic strain rate was 1,6±0.5; the mean 
early diastole strain rate was -1,6±0,6 and the mean late diastole strain rate was -1,4±0,8. The 
mean LV GLS was -18,8±5,3 % and 51,4% (n=18) presented LV GLS >-20%. The 
echocardiographic patients’ characteristics can be consulted in Table 3. 
 
3.4 Clinical and analytical variables according to the presence of echocardiographic 
markers of DD 
The Clinical and analytical characteristics vary among the groups with positive echocardiographic 
markers of DD. E/e’ ratio was excluded from further analysis, because it was less than 14 in all 
patients and therefore statistically irrelevant. 
It should be noted that the average age value is higher when the LV GLS >-20% and a LA 
maximum volume index >34 mL/m2, and so is the mean PASI and systolic BP. In contrast, the 
average BMI, abdominal perimeter and diastolic BP was higher in the group with LV GLS >-
20%. On the other hand, the mean disease evolution was higher in the group with LA maximum 
volume index >34 mL/m2 (see Table 4). 
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About the analytical variables, there are also different patterns associated. The HDL mean value 
was lower and the LDL mean value was higher where the two criteria met, as for the total 
cholesterol, apolipoprotein B and hsCRP. The average triglycerides and C3 values were higher in 
the group with LV GLS >-20%, whereas the NT-proBNP mean value was higher in the group 
with LA maximum volume index >34 mL/m2 (see Table 5). 
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4. Discussion 
Psoriasis has a substantially high prevalence and requires lifelong topic and/or systemic 
therapy.[31] However, the information regarding echocardiographic parameters in psoriasis 
patients is not profuse. It is very important to identify and manage patients with psoriasis, 
particularly those with underlying cardiovascular risk factors and/or metabolic syndrome[10], 
since psoriasis has been consistently described as an independent risk factor for cardiovascular 
disease.[12, 32] Echocardiography analysis, particularly STE, offers several advantages, 
specifically it evaluates LV functions more objectively and quantitively and is not subject to EF 
limitations. Also, this analysis is angle-independent, reproducible and quantitative, so the utility 
of this examination is further increased.  
LV DD is usually the result of an abnormal LV relaxation with or without reduced resting forces 
and early diastolic suction, and increased LV chamber stiffness, which increase cardiac filling 
pressures. DD is common in the population, with some studies suggesting a prevalence in general 
population of 20,8% mild DD, 6,6% moderate DD and 0,7% severe DD. Hence, DD is often not 
accompanied by recognized heart failure and is established in recent studies as an independent 
risk factor for the development of heart failure and marked increase in all-cause long term 
mortality.[19] Moreover, filling patterns in the elderly resemble those observed in mild diastolic 
dysfunction in younger patients, and, so, age should be taken into account when evaluating 
diastolic function variables.[33] HFpEF, which results from a complex interplay between genetic, 
neurohormonal, inflammatory, and biochemical changes acting on cardiac myocytes and the 
cardiac interstitium, is typically characterized by the presence of diastolic dysfunction. 
Several studies have recently reiterated echocardiographic changes in relation to systolic and /or 
diastolic function in psoriasis patients. Ahlehof, et al. (2016), prospectively studied 18 severe 
psoriasis patients treated with biologic therapy and compared myocardial function at baseline and 
after three months of treatment. The study group demonstrated an improvement in myocardial 
function (E/e’ and GLS), in addition to the improvement of the PASI.[34] Atas, et al. (2015), 
assessed left atrial volume and function in psoriasis patients and healthy controls through 
conventional, tissue Doppler and 3D echocardiography. Although there were no significant 
differences between these groups, psoriasis patients had a higher incidence of left ventricular 
diastolic dysfunction and higher LA phasic volumes (LA maximum, minimum, passive stroke 
and passive emptying fraction) and impaired LA mechanical function (LA active emptying 
fraction, total emptying fraction, expansion index and active stroke volume).[35] Örem, et al. 
(2013) assessed biochemical and echocardiographic markers in 31 psoriasis patients and healthy 
controls and firstly described LV asynchrony as independent associated with psoriasis.[36] Gullu 
et al. (2013) studied 36 psoriasis patients and 56 healthy controls and coronary flow reserve is 
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decrease in the psoriasis group and was significantly and inversely correlated with disease 
duration, PASI score and hsCRP.[37] Simsek, et al. (2013) compared 94 psoriasis patients and 51 
healthy controls and concluded that psoriasis patients have significant echocardiographic 
abnormalities, namely longer transmitral DT and isovolumetric relaxation time, and that 
electrocardiographic findings, such as greater P wave dispersion and QT dispersion correlated 
with disease duration. [38] Biyik, et al. (2006), investigated the incidence and severity of 
echocardiographic and clinical abnormalities in patients with different types of psoriasis and 
concluded that echocardiographic abnormalities, particularly left ventricular diastolic 
dysfunction, were significantly more frequent in patients with psoriasis, but also LV hypertrophy, 
LV wall motion abnormalities, mitral valve and tricuspid valve prolapse. [32] It is not to be 
despised that, in some cases, diastolic dysfunction occurs in patients without classic 
cardiovascular risk factors.[39] 
On the other hand, the fact that therapeutic interventions suppressing the systemic 
proinflammatory process in psoriasis can reduce coronary microvascular dysfunction[40] and has 
a potentially beneficial effect on subclinical cardiovascular disease signs[41], corroborates, in 
some way, the abovementioned investigations. Recent studies have concluded that TNF-α 
inhibitors treatment ameliorates CMD in patients with established psoriasis not responding to 
long-term conventional therapy and thus suggest that a therapy specifically targeted against 
inflammation can positively affect coronary microvascular function.  
Therefore, the present study is in line with the described literature, representative of the state of 
the art. Since our study group has very homogenous characteristics, it was not possible to divide 
and test the causality of certain parameters, such as psoriasis severity, biological therapy or 
disease duration. Thus, since it is a pilot study, it is more pertinent to make an exhaustive 
description of the statistically relevant data, and its variation according to the widely accepted 
diastolic dysfunction markers, and integrate it in the light of the most recent literature.  
A high prevalence of cardiovascular disease risk factors was found in this study group, namely 
high abdominal perimeter, obesity, hypertension, diabetes mellitus and lipid profile abnormalities 
in psoriasis patients.  
Regarding psoriasis markers, the mean evolution of the disease was highest in patients with LA 
maximum volume index >34 mL, suggesting that the cumulative exposure to this 
proinflammatory state may play a role in the development of DD. 
Amongst biomarkers of myocyte stress, ventricular NT-proBNP synthesis is markedly increased 
in the failing heart and, compared to BNP, it has a longer half-life and is biologically inert.[42] 
Although the increase in NT-proBNP levels is less pronounced in HFNEF, higher plasma NT-
proBNP levels are shown to be associated with greater severity of diastolic dysfunction in patients 
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with HFNEF and are strong predictors of mortality and hospitalizations.[43] Recently, some 
studies have proven that NT-proBNP concentrations were significantly higher in psoriasis 
patients and there is a positive correlation between this marker and psoriasis duration.[44] The 
present study describes a great increase in NT-proBNP values in patients with LA maximum 
volume index >34 mL when compared to the average. Nonetheless, further investigation is 
mandatory to validate NT-proBNP as a useful biomarker of CV disease. 
Inflammatory biomarker levels may be a measure of factors driving LV remodelling in HFNEF. 
hsCRP is produced in the liver in response to stimulation of various cytokines, mostly IL-6.[42] 
hsCRP is a sensitive marker and is applied to predict and diagnose low-grade inflammatory 
conditions. Furthermore, hsCRP has been established as an independent predictor of prognosis in 
heart failure and can provide additional information for the risk stratification, as well as the 
response of HF patients to treatment[45]. This study refers a higher hsCRP mean in patients with 
both LA maximum volume index >34 mL and LV GLS >-20%. As for C3, the mean value was 
highest in patients with LV GLS >-20%. 
The ratio of the peak early mitral inflow velocity (E) over the early diastolic mitral annular 
velocity (e′) has gained wide acceptability in routine clinical practice[29] as an echocardiography 
marker of diastolic dysfunction. In the present study, the E/e’ value was normal in every single 
patient and therefore was not useful in this discussion. Alternatively, other indirect measures of 
DD were significantly abnormal in this study group, as is the case with the E/A ratio that was 
below 0,75 in 10,8% and above 1,5 in 8,1%; and DT that was greater than 220 ms in 44,4% 
patients. 
Although there is no recommended universal normal range of values for LV GLS, due to 
considerable differences among vendors and software packages, a peak GLS in the range of -20% 
can be expected in healthy individuals and the lower absolute value below this, the more likely it 
is to be abnormal[29], which was the case for 47,4% of patients in this study. 
 
Limitations of the Study 
This investigation lacks the power and randomization that only large and randomized study 
groups and matched control subjects can provide. Secondly, follow up data is necessary to 
establish prognostic and progression significance of LV subclinical diastolic dysfunction.  
All patients in this study had moderate-to-severe psoriasis, though they may have presented low 
PASI at consultation, this is because they were controlled by biological treatment. Besides, the 
fact that some patients were medicated for other comorbidities may have influenced the values of 
certain parameters, such as serum lipid values, BP measurements and inflammation markers, 
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undercovering the true values, since it has been demonstrated that control of these comorbidities 
can have a positive impact on cardiovascular disease. The presence of potential adverse effects of 
systemic antipsoriatic drugs may also contribute to the observed associations.   
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5. Conclusion 
In conclusion, echocardiography analysis, particularly with STE shows promising prospects in 
early identification of diastolic dysfunction in psoriatic patients. Together, in patients with LA 
maximum volume index >34 mL and LV GLS >-20%, the average PASI was highest, as well as 
age values. Also, hsCRP may have a role in detecting low grade inflammatory states and predict 
long-term repercussions of chronic inflammatory states since a higher hsCRP mean was found in 
patients with both LA maximum volume index >34 mL and GLS >-20%. 
However, further research is required to support the abovementioned premises and identify 
effective interventional strategies capable of delaying the inevitability of these repercussions 
resulting from this proinflammatory state. 
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7. Tables 
 
Table 1. Demographic and Clinic Patients’ Characteristics 
Characteristic Value 
Age, years 47,5 
Male, % 68,4 
PASI 3,2 ± 3,5 
Evolution Psoriasis, years 21 ± 13,7 
Biologic Therapy, % 92,1 
Psoriatic Arthritis, % 44,7 
Current Smoker, % 36,8 
Inactive, % 76 
BMI, kg/m2 27,6 ± 4,5 
Body Surface Area, m2 1,9 ± 0,2 
Abdominal Perimeter, cm 97 ± 12 
Systolic BP, mmHg 128 ± 15 
Diastolic BP, mmHg 79 ± 9 
PASI, Psoriasis Area and Severity Index; BMI, Body Mass Index; BP, Blood Pressure. 
 
Table 2. Analytic Patients' Characteristics 
Characteristic Value 
LDL, mg/dL 117 ± 41 
HDL, mg/dL 52 ± 13 
Total Cholesterol, mg/dL 196 ± 41 
Triglycerides, mg/dL 114 ± 72 
Apolipoprotein B, mg/dL 102 ± 22 
NT-proBNP, pg/mL 40,4 ± 38,4 
Complement Component 3, mg/dL 115,3 ± 21,5 
High Sensitive C-Reactive Protein, mg/L 3,6 ± 3,9 
HbA1c, % 5,3 ± 0,4 
LDL, Low-Density Lipoprotein; HDL, High-Density Lipoprotein; NT-proBNP, N-terminal pro-B-type Natriuretic 
Peptide; C3, Complement Component 3; HsCRP, High-Sensitive C-Reactive Protein; HbA1c, Glycated hemoglobin. 
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Table 3. Echocardiographic Patients’ Characteristics 
Characteristic Value Characteristic Value 
Septal wall thickness, mm 9,97 ± 1,8 LA Maximum Atrial Volume, mL 69,8 ± 21,6 
Posterior wall thickness, mm 8,99 ± 1,6 LA Pre-A Wave Atrial Volume, mL 37 ± 16,4 
LV EDVi, mL/ m2 52,8 ± 34,7 LA Minimum Atrial Volume, mL 18,2 ± 9,4 
LV ESVi, mL/ m2 19,1 ± 4,5 LA emptying fraction 74,5 ± 8,1 
LV EF, % 58 ± 3 LA expansion index 359,5 ± 158,9 
FS, % 37,5 ± 6,5 LA passive emptying volume, mL 31,6 ± 12,9 
E, cm/s 71,72 ± 12,3 LA passive emptying fraction 47,6 ± 16,3 
A, cm/s 69,77 ± 13,08 LA active emptying volume, mL 19 ± 8,9 
DT, ms 222 ± 56 LA active emptying fraction 51,9 ± 11 
E/A  1,08 ± 0,317 PALS, % 51,3 ± 18,6 
Medial e’, cm/s 10,541 ± 2,667 PACS, % 19,5 ± 7,8 
Lateral e’, cm/s 13,7 ± 4 PALS - PACS, % 32,2 ± 17,1 
Average e’, cm/s 12,1 ± 3,3 Systolic Strain Rate 1,6 ± 0.5 
Medial E/e’ 7,2 ± 1,7 Early Diastole Strain Rate -1,6 ± 0,6 
Lateral E/e’ 5.5 ± 1,3 Late Diastole Strain Rate -1,4 ± 0,8 
Average E/e’ 6,3 ± 1,5 LALS, % -18,8 ± 5,3 
LV Left Ventricular; LV EDV/ESV Left Ventricular End-Diastolic/End-Systolic Volume; FS Fractional shortening; 
DT Deceleration Time; LA Left Auricular; PALS Peak Atrial Strain at the End of Ventricular Systole; PACS Peak 
Atrial Strain before Atrial Contraction; LALS Left Auricular Longitudinal Strain. 
 
Table 4. Demographic and Clinical Data According to Echocardiographic Characteristics 
Characteristic GLS  
> -20% 
LA max. vol. 
index >34 mL 
GLS  
> -20% and LA max. vol. 
index >34 mL 
Age, years 48 ± 10 48 ± 11 50 ± 11 
PASI 3 ± 4 3 ± 3 3,7 ± 4,5 
Evolution Psoriasis, years 21 ± 13 22 ± 14 20 ± 15 
BMI kg/m2 29 ± 5 28 ± 4 28,7 ± 4,1 
Abdominal Perimeter, cm 100 ± 12 95 ± 12 99 ± 12 
Systolic BP, mmHg 135 ± 14 128 ± 14 135 ± 13 
Diastolic BP, mmHg 84 ± 8 79 ± 10 83 ± 10 
PASI, Psoriasis Area and Severity Index; BMI, Body Mass Index; BP, Blood Pressure; GLS, Global Longitudinal 
Strain; LA max. vol. index, LA Maximum Volume Index. 
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Table 5. Analytic Data According to Echocardiographic Characteristics 
Characteristic GLS  
> -20% 
LA max. vol. index 
 >34 mL 
GLS  
> -20% and LA max. vol. 
index >34 mL 
LDL, mg/dL 136 ± 39 122 ±37 144 ± 45 
HDL, mg/dL 51 ± 13 49 ± 12 48 ± 9 
Total Cholesterol, mg/dL 211 ± 45 194 ± 42 215 ± 52 
Triglycerides, mg/dL 121 ± 64 116 ± 75 115 ± 34 
Apolipoprotein B, mg/dL 111 ± 22 104 ± 24 113 ± 29 
NT-proBNP, pg/mL 15,6 ± 12 48 ± 43 20,3 ± 14,3 
C3, mg/dL 121,6 ± 22,9 108 ± 19 114,7 ± 22,5 
hsCRP, mg/L 4 ± 4,4 4,4 ± 4,3 6,2 ± 5,4 
HbA1c, % 5,3 ± 0,4 5,3 ± 0,4 5,3 ± 0,4 
LDL, Low-Density Lipoprotein; HDL, High-Density Lipoprotein; NT-proBNP, N-terminal pro-B-type Natriuretic 
Peptide; C3, Complement Component 3; HsCRP, High-Sensitive C-Reactive Protein; HbA1c, Glycated hemoglobin; 
GLS, Global Longitudinal Strain; LA max. vol. index, LA Maximum Volume Index. 
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8. Figures 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Apical two-chamber view. 
Figure 2 Apical four-chamber view. 
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Figure 3 Apical chamber view, longitudinal strain curve of the Left Auricle by speckle tracking echocardiography. 
